Display options
Cite
McBride WJ, Sharkey RM, Goldenberg DM. Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res. 2013;3(1):36doi: 10.1186/2191-219X-3-36.
McBride, W. J., Sharkey, R. M., & Goldenberg, D. M. (2013). Radiofluorination using aluminum-fluoride (Al18F). EJNMMI research, 3(1), 36. https://doi.org/10.1186/2191-219X-3-36
McBride, William J, et al. "Radiofluorination using aluminum-fluoride (Al18F)." EJNMMI research vol. 3,1 (2013): 36. doi: https://doi.org/10.1186/2191-219X-3-36
McBride WJ, Sharkey RM, Goldenberg DM. Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res. 2013 May 08;3(1):36. doi: 10.1186/2191-219X-3-36. PMID: 23651690; PMCID: PMC3665500.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2013 May 08;3(1):36. doi: 10.1186/2191-219X-3-36.

Radiofluorination using aluminum-fluoride (Al18F).

EJNMMI research

William J McBride, Robert M Sharkey, David M Goldenberg

Affiliations

  1. Immunomedics, Inc,, 300 The American Road, Morris Plains, NJ 07950, USA. [email protected].

PMID: 23651690 PMCID: PMC3665500 DOI: 10.1186/2191-219X-3-36

Abstract

Targeted agents are increasingly used for treating cancer and other diseases, but patients may need to be carefully selected to maximize the potential for therapeutic benefit. One way to select patients is to bind an imaging radionuclide to a targeting agent of interest, so that its uptake in specific sites of disease can be visualized by positron-emission tomography (PET) or single-photon emission computed tomography.18F is the most commonly used radionuclide for PET imaging. Its half-life of approximately 2 h is suited for same-day imaging of many compounds that clear quickly from the body to allow visualization of uptake in the intended target. A significant impediment to its use, however, is the challenging coupling of 18F to a carbon atom of the targeting agent. Because fluorine binds to aluminum, we developed a procedure where the Al18F complex could be captured by a chelate, thereby greatly simplifying the way that imaging agents can be fluorinated for PET imaging. This article reviews our experience with this technology.

References

  1. Eur J Nucl Med Mol Imaging. 2008 May;35(5):1008-18 - PubMed
  2. J Nucl Med. 2010 Mar;51(3):454-61 - PubMed
  3. Biochem Biophys Res Commun. 1988 Sep 30;155(3):1194-200 - PubMed
  4. J Nucl Med. 2012 Jun;53(6):947-52 - PubMed
  5. J Med Chem. 2002 Aug 1;45(16):3458-64 - PubMed
  6. Bioconjug Chem. 2011 Sep 21;22(9):1793-803 - PubMed
  7. Nat Med. 2005 Nov;11(11):1250-5 - PubMed
  8. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12462-7 - PubMed
  9. J Inorg Biochem. 2002 Jan 1;88(1):1-6 - PubMed
  10. J Nucl Med. 2013 May;54(5):691-8 - PubMed
  11. Am J Nucl Med Mol Imaging. 2013;3(1):44-56 - PubMed
  12. Mol Cancer Ther. 2010 Apr;9(4):1019-27 - PubMed
  13. Anal Chem. 2005 Apr 15;77(8):2437-49 - PubMed
  14. Angew Chem Int Ed Engl. 2008;47(47):8998-9033 - PubMed
  15. J Nucl Med. 2000 Oct;41(10):1704-13 - PubMed
  16. Eur J Nucl Med. 1998 Feb;25(2):201-12 - PubMed
  17. Theranostics. 2012;2(5):481-501 - PubMed
  18. Bioorg Med Chem. 2012 Oct 1;20(19):5941-7 - PubMed
  19. Nucl Med Biol. 1994 Nov;21(8):1023-34 - PubMed
  20. J Nucl Med. 2011 Feb;52(2):270-8 - PubMed
  21. Bioconjug Chem. 2006 Sep-Oct;17(5):1294-313 - PubMed
  22. Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):463-73 - PubMed
  23. Theranostics. 2012;2(10):999-1009 - PubMed
  24. PLoS One. 2012;7(5):e37506 - PubMed
  25. Theranostics. 2013;3(3):181-9 - PubMed
  26. J Am Chem Soc. 2012 Oct 24;134(42):17456-8 - PubMed
  27. Theranostics. 2012;2(5):523-40 - PubMed
  28. Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1732-41 - PubMed
  29. Appl Radiat Isot. 2012 Jan;70(1):200-4 - PubMed
  30. J Nucl Med. 2011 Sep;52(9):1441-8 - PubMed
  31. Bioconjug Chem. 2010 Jul 21;21(7):1331-40 - PubMed
  32. J Nucl Med. 2009 Jun;50(6):991-8 - PubMed
  33. Chem Rev. 2008 May;108(5):1501-16 - PubMed
  34. Curr Top Med Chem. 2010;10(16):1669-79 - PubMed
  35. J Nucl Med. 2012 Jan;53(1):146-53 - PubMed
  36. Dalton Trans. 2011 Jun 21;40(23):6196-205 - PubMed
  37. Crit Rev Oral Biol Med. 2003;14(2):100-14 - PubMed
  38. J Med Chem. 2012 Apr 12;55(7):3155-62 - PubMed
  39. Bioconjug Chem. 2011 May 18;22(5):894-902 - PubMed
  40. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):683-92 - PubMed
  41. J Biol Chem. 1992 Apr 5;267(10):6710-8 - PubMed
  42. Chem Commun (Camb). 2011 Sep 14;47(34):9732-4 - PubMed
  43. Bioconjug Chem. 2012 Mar 21;23(3):538-47 - PubMed
  44. Tumour Biol. 2012 Apr;33(2):427-34 - PubMed
  45. Contrast Media Mol Imaging. 2013 May-Jun;8(3):238-45 - PubMed
  46. Science. 1982 Mar 19;215(4539):1511-3 - PubMed
  47. Bioconjug Chem. 2011 Dec 21;22(12):2415-22 - PubMed

Publication Types